Hong Kong’s CK Life To Spin Off U.S. R&D Unit Polynoma, Keep Control
This article was originally published in PharmAsia News
Hong Kong’s CK Life Sciences International intends to establish its U.S.-based subsidiary, Polynoma, as a separate company for research and development, including work on a vaccine for melanoma set to enter Phase III trials.
You may also be interested in...
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.